P atients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular disease (CVD). This complication accounts for much of the increased morbidity, mortality and costs of care associated with diabetes. Hypertension, dyslipidaemia, a pro-inflammatory phenotype, abnormal fibrinolysis and platelet activation, insulin resistance and high blood glucose concentrations all contribute to the increased risk of macrovascular disease in diabetes. Although reducing low-density lipoprotein (LDL)-cholesterol, controlling blood pressure, angiotensin-converting enzyme (ACE) inhibitors and aspirin have been shown to decrease CVD in diabetes, it is less clear that lowering glucose levels decreases risk. The PROactive trial was undertaken to test whether treatment with the thiazolidinedione pioglitazone could decrease the number of CVD events in high-risk patients with T2DM.
Introduction
A global epidemic of diabetes emerged in the latter half of the 20th century and continues unchecked. In the United States alone, diabetes affects more than 20 million persons or about 7% of the population. 1 Worldwide, more than 150 million people are affected by diabetes, and this number is expected to more than double in the next 25 years. 2, 3 Patients with type 2 diabetes mellitus (T2DM) are at high risk for fatal and non-fatal macrovascular events. In the Framingham Heart Study, DM was associated with a 2-to 4fold higher risk of coronary heart disease and stroke while the risk of congestive heart failure (CHF) among those with DM was 6-to 10-fold higher than among those without. 4 In the recent Heart Protection Study, patients with DM and a history of cardiovascular disease (CVD) at study entry had a risk of a new cardiovascular (CV) event nearly three times higher than the risk among those without DM. 5 A Finnish study of 1,059 persons with DM and 1,373 persons without, who were followed for seven years, demonstrated that the incidence of either fatal or non-fatal acute myocardial infarction (MI) among those with DM was comparable to the incidence among those with a prior CV event but without DM (18.8% vs. 20.2%). 6 These data, as well as comparable findings from other trials, have led many clinicians to consider DM a 'CVD equivalent'. Largely because of an increased risk of macrovascular disease, life expectancy is about eight years shorter in a 40-year-old patient newly diagnosed with DM. 7 Macrovascular disease is, therefore, the most important complication of DM, contributing to increased morbidity, mortality and costs of care.
The reasons for the increased risk of CVD among patients with DM are not completely understood but it is likely that both traditional and non-traditional risk factors play a role. In addition to higher rates of hypertension and dyslipidaemia, persons with DM also manifest insulin resistance, a proinflammatory phenotype characterised by chronically elevated circulating biomarkers of inflammation (such as C-reactive protein [CRP]), abnormalities in fibrinolysis (particularly increases in plasminogen activator inhibitor-1) and platelet activation. There is also evidence from several large prospective studies that high blood glucose concentrations per se are associated with a greater incidence of CVD among persons with DM. 8 Interventions such as reducing low-density lipoprotein (LDL)-cholesterol, controlling blood pressure, angiotensinconverting enzyme (ACE) inhibitors and aspirin have been shown to lower CV morbidity and mortality in DM. In contrast, the evidence that improving glycaemic control decreases CVD is less robust. In the UK Prospective Diabetes Study (UKPDS), intensive glucose control that lowered glycosylated haemoglobin (HbA 1C ) by 0.9% relative to usual care was associated with a 16% reduction in MI (p=0.052). In a subgroup of obese subjects treated with metformin, a 32% reduction in any DM-related end point (p<0.002) and a 39% reduction in MI (p<0.01) were observed. 9 Paradoxically, the risk for CVD was higher in patients treated with sulfonylureas in whom metformin was added as second-line therapy. 10 In a 10-year, epidemiological follow-up study of patients with T1DM who participated in the Diabetes Control and Complications Trial (DCCT), 11 lower rates of CVD were observed in the group initially randomised to intensive glucose control. Neither the UKPDS nor the DCCT was powered to detect a reduction in CVD, however. Thus, while these data suggest that improved glycaemic control may itself decrease CVD, there remain many unanswered questions. In particular, it is not known whether newer classes of drugs for T2DM such as the thiazolidinediones (TZDs) will have beneficial effects.
Pioglitazone for the treatment of T2DM
Pioglitazone is an oral TZD that is approved for the treatment of T2DM, as monotherapy and in combination with metformin, sulfonylureas and insulin. The drug is a potent agonist of peroxisome proliferator-activated receptor (PPAR)γ, 12 as are other members of this class. Working through PPARγ, pioglitazone sensitises peripheral tissues (including adipocytes) 13, 14 to the effects of insulin. In addition, pioglitazone has other non-glycaemic effects, including improving high-density lipoprotein (HDL) cholesterol, decreasing triglycerides, increasing the size of LDL particles and decreasing biomarkers of inflammation such as CRP. 15 In vitro and animal studies have demonstrated that pioglitazone also has a number of other effects, including inhibition of smooth muscle proliferation, 16 cell migration 17 and decreasing vascular inflammation, suggesting that it might have particularly beneficial effects which decrease the atherosclerotic process. These data led to the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) trial, 18 which tested whether pioglitazone treatment could reduce CVD events in high-risk patients with T2DM.
The PROactive trial Design
The PROactive study was a prospective, multicentre, randomised, double-blind, placebo-controlled trial. The study enrolled patients with T2DM whose HbA 1C was >6.5% and who had evidence of CVD at the time of randomisation. Around 30% of patients were being treated with insulin, mostly in combination with oral agents, at the time of randomisation. All patients were continued on their existing diet, glucose-lowering agents (including insulin), antihypertensive medications, lipid-lowering agents and antithrombotic agents. Patients were randomised to receive either pioglitazone (n=2,605) titrated to 45 mg/day or matching placebo (n=2,633). Subjects were followed for an average of 34.5 months. Patients were seen monthly for the first two months, then every two months for the first year, and thereafter every three months until the final visit. All patients were followed until the end of the study, even if they discontinued study medication. Sixteen percent of patients in the pioglita-zone group and 17% in the placebo group stopped taking the study medication before the end of the study.
All potential end points were adjudicated by an independent committee. The primary end point was a composite of all-cause mortality, non-fatal MI, stroke, acute coronary syndrome, endovascular or surgical intervention in coronary or leg arteries, or amputation above the ankle. A number of secondary end points were also specified, including a composite of all-cause mortality, non-fatal MI and stroke.
Main results
Pioglitazone treatment decreased the primary composite end point by 10% (514 events in the pioglitazone group versus 572 events in the placebo group); however, this difference did not attain statistical significance (p=0.095). When the main secondary composite end point of all-cause mortality, non-fatal MI and stroke was analysed, there was a 16% reduction in the pioglitazone group compared with the placebo group (301 events in the pioglitazone group versus 358 in the placebo group). This difference was statistically significant (p=0.027). There were no significant differences in rates of coronary revascularisation between the two groups, but increased numbers of patients treated with pioglitazone underwent leg revascularisation procedures.
Other findings
Among patients treated with pioglitazone, the absolute change in HbA 1C from baseline to final visit was -0.8%, compared with -0.3% in those assigned to placebo (p<0.0001). There were also small, but significant, decreases in systolic blood pressure in the pioglitazone group of 3 mmHg (p<0.03). Pioglitazone treatment decreased triglycerides by 11% versus 1% in the placebo group (p<0.0001); LDL increased by 7% versus 5% (p=0.003) and HDL increased by 19% versus 10% (p<0.0001). Pioglitazone also markedly decreased the numbers of patients progressing to insulin use over the course of the study (by 53%, p<0.0001).
Safety
In general, pioglitazone treatment was well tolerated. Rates of adverse events were comparable in both groups. However, the number of patients who reported any episode of heart failure (HF) was higher in pioglitazone-treated patients compared with controls (11% vs. 8%, relative risk = 1.4, p<0.0001). The percentage of patients with HF requiring admission was also higher in the pioglitazone group (6% vs. 4%, relative risk = 1.4, p=0.007), but there were no differences in deaths related to HF. Body weight increased by an average of 3.6 kg in the pioglitazone-treated group compared with a decrease of 0.5 kg in the placebo group.
Analysis
The PROactive study is the first adequately-powered study to look at the secondary prevention of macrovascular events in T2DM with hypoglycaemic agents. Unfortunately, the results of the study are not definitive and raise as many questions as they answer. The simplest interpretation of the findings is that pioglitazone does not reduce CVD events significantly, and this is certainly true if only the primary end point PERSPECTIVES is considered. However, the main secondary composite end point of all-cause mortality, non-fatal MI and stroke was significantly lower in the group randomised to pioglitazone treatment. Importantly, this definition is an accepted standard that has been used in many prior CVD outcome trials. The inclusion of other elements in the primary end point such as coronary and leg revascularisation, which was evidently done to increase the power of the analysis, may have actually diluted the results. Purists would argue that it is only legitimate to consider secondary end points if the primary end point has been met. Since it was not met in this case, they would say that the reduction in the main secondary end point is meaningless. Pragmatists, on the other hand, recognise that clinical trial design is an imperfect science and often entails compromises. Rather than completely discounting the main secondary end point, this group may interpret the results as suggestive of a CVD benefit.
A number of other issues with the trial are worth highlighting. The vast majority of the participants were Caucasian (~98%), so whether the results (however they are interpreted) apply to other racial and ethnic groups is not known. The use of agents known to have benefit in the secondary prevention of CVD, such as aspirin, statins and ACE inhibitors, was suboptimal (75%, 43% and 70%, respectively). Low rates of statin use, in particular, may have contributed to the higher than expected event rates observed in the trial and, thus, termination of this event-driven trial more than a year earlier than projected. How this affected the outcome of the trial is not clear. On the one hand, the shorter duration of exposure to pioglitazone may have decreased the opportunity for the drug to exert its beneficial effects. Conversely, the higher CVD risk of the population may have enhanced the apparent effect of pioglitazone above that which would be anticipated in optimally treated patients.
It is not clear whether the effect of pioglitazone on macrovascular end points is a unique property of the drug or whether it reflects the small, albeit significant, improvements in glucose, blood pressure and lipids in aggregate. Nontraditional markers of CVD risk such as CRP, which might have provided further insight, were not measured.
The finding that pioglitazone significantly decreased the numbers of patients progressing to insulin may indicate that the drug modifies the natural history of the decline in beta cell function over time in some way. However, in the absence of an active control, it is not possible to conclude that this a specific effect of the drug rather than simply the result of being treated with an additional glucose-lowering agent.
Finally, the 40% higher risk of symptomatic CHF with pioglitazone treatment needs to be acknowledged. The increase in CHF is perhaps unsurprising in this high-risk group with prior CVD, especially since many patients were being treated with insulin. Unfortunately for the study, heart failure events (except those resulting in death) were not adjudicated by the independent panel. This may have led to an overestimation of events in pioglitazone-treated patients who developed oedema. While there did not appear to be excess mortality due to CHF in pioglitazone-treated patients, these data remind clinicians that symptomatic CHF is a potential risk of TZD treatment that needs to be balanced against the expected benefit from using these agents.
Implications for practice Pioglitazone is an effective and safe treatment for patients with T2DM
This study demonstrates clearly that pioglitazone significantly improved glycaemic control in patients with T2DM who were on a variety of treatments. Adverse events were comparable in pioglitazone-and placebo-treated patients, with the exception of a greater weight gain and a higher rate of CHF. The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have recently endorsed guidelines that recommend metformin for the initial treatment of hyperglycaemia in T2DM. 19 The selection of metformin was based on a number of factors, including efficacy, safety and cost. The data from the present study do not support moving TZDs to an earlier position in the treatment paradigm. They do indicate, as the EASD and ADA suggest, that TZDs are an effective second-line therapy.
Pioglitazone and CVD risk reduction
Patients treated with pioglitazone were not at any increased risk for death, MI or stroke, and may have experienced a small benefit. Further studies are necessary before pioglitazone can be recommended specifically for reduction of CVD events. Pioglitazone treatment was also associated with slight improvements in CVD risk factors, including systolic blood pressure, triglycerides and HDL-cholesterol. Although they are statistically significant and meaningful on a population basis, these improvements would be unlikely to get individual patients to goal. Thus, pioglitazone should be used in conjunction with a broader CVD risk factor reduction regimen, to include aspirin, statins and ACE inhibitors.
Pioglitazone and CHF
The incidence of symptomatic CHF was slightly higher in pioglitazone-treated patients in the PROactive study. Of note, however, mortality from CHF was not increased. Given that these patients had pre-existing CVD, it is surprising that this event was not more frequent. This result confirms the increased risk of CHF with TZD treatment that has been observed in prior studies. Thus, existing clinical recommendations for using TZDs with caution in patients who have a history of CHF or who are at risk of heart failure seem justified.
Summary
The PROactive study is an important milestone as it is the first robust trial to address CVD risk reduction with DM treatment. Although the results of PROactive did not demonstrate definitively that pioglitazone reduces CVD, the data do indicate that drugs in this class can be used safely in patients with T2DM and CVD, and provide encouragement that TZDs may offer a CV benefit. Clearly, further trials are required. Many are already underway, including the Action to Control CardiOvascular Risk in Diabetes (ACCORD) study, the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetic patients with CV History (APPROACH) study, and the Bypass Angioplasty Revascularisation Investigation in T2DM (BARI-2D) study. The principal investigators of these and future trials would be well advised to learn from the lessons of PROactive by carefully considering the definition of the primary end point and analysis strategy and by incorporating measurements of newer, non-traditional risk factors into the study design.
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